Lipocalin-1, also known as tear lipocalin, is a multifunctional protein predominantly recognized for its role in the transport of small hydrophobic molecules, including lipids, hormones, and vitamins. It is part of the lipocalin family, proteins known for their ability to bind and transport a diverse array of ligands, thereby playing crucial roles in various physiological processes such as inflammation, immune responses, and the regulation of cellular homeostasis. Lipocalin-1, in particular, exhibits a broad binding specificity, which allows it to participate in the stabilization of cell membranes, modulation of cell signaling, and protection of cells against oxidative stress and damage. This protein is secreted by various tissues, including lacrimal glands, and is present in numerous bodily fluids, highlighting its importance in maintaining the health and function of multiple organ systems.
The inhibition of Lipocalin-1's activity can occur through several mechanisms, reflecting the complexity of its biological functions and the pathways it is involved in. One mechanism is the direct interaction with inhibitors that block the ligand-binding site, preventing Lipocalin-1 from binding to its natural substrates. This would effectively reduce its ability to transport and modulate the availability of hydrophobic molecules within the body. Another mechanism could involve the modulation of its expression through genetic or epigenetic modifications, leading to decreased protein synthesis and secretion. Additionally, post-translational modifications, such as phosphorylation, glycosylation, or ubiquitination, could alter the structural conformation or stability of Lipocalin-1, impairing its functionality. Furthermore, changes in the cellular or extracellular environment, such as alterations in pH, ion concentration, or the presence of oxidative stress, could also negatively impact Lipocalin-1's activity. These inhibitory mechanisms ensure that the activity of Lipocalin-1 is tightly regulated, allowing it to effectively contribute to the physiological processes it is involved in while preventing dysregulation that could lead to disease states.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine, a DNA methyltransferase inhibitor, could affect LCN1 expression by influencing DNA methylation patterns. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
This histone deacetylase inhibitor may affect LCN1 expression by altering chromatin structure and gene expression. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
By binding to DNA and inhibiting RNA synthesis, this compound could potentially affect the expression of LCN1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor like rapamycin might indirectly influence LCN1 expression by affecting protein synthesis pathways. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 inhibits the proteasome, affecting protein degradation, which could influence LCN1 levels in cells. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
This compound inhibits protein synthesis, potentially reducing LCN1 levels by blocking translation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
By inhibiting PI3K, LY294002 could affect pathways that influence LCN1 expression, such as the mTOR pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
This JNK inhibitor could affect LCN1 expression by influencing various cellular transcription processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAPK, potentially affecting LCN1 expression by influencing protein stability and gene expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibiting MEK with PD98059 affects the ERK pathway, potentially influencing gene expression and thus LCN1 levels. | ||||||